Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Kasraeian Urology, a Division of Florida Physician Specialists (“Kasraeian Urology”). FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner.

“Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional MRIs, and paving way for our $3 billion addressable market for in-office prostate procedures. We are thrilled to welcome Kasraeian Urology to our growing network of physician practices and look forward to our partnership to improve upon overall patient cancer care in the office setting,” said Dr. Amit Vohra, Founder, and CEO of Promaxo.

Dr. Ali Kasraeian, FACS at Kasraeian Urology said, “Our practice is dedicated to providing the most current and accurate tools and techniques for identifying and treating prostate cancer. The Promaxo system reinforces our practice goals as it not only allows us to refine our biopsies, but also facilitates MR-guided therapies within the comfort of our offices and ambulatory surgery center. We are delighted to be able to offer this new technology and service to our patients.”

Source: Company Press Release